PMID- 21055651
OWN - NLM
STAT- MEDLINE
DCOM- 20110324
LR  - 20220317
IS  - 1532-8414 (Electronic)
IS  - 1071-9164 (Linking)
VI  - 16
IP  - 11
DP  - 2010 Nov
TI  - Serum YKL-40 predicts adverse clinical outcomes in patients with chronic heart 
      failure.
PG  - 873-9
LID - 10.1016/j.cardfail.2010.05.029 [doi]
AB  - BACKGROUND: Human cartilage glycoprotein-39 (YKL-40), a novel inflammatory 
      marker, is secreted into circulation by macrophages, neutrophils, chondrocytes, 
      vascular smooth muscle cells and cancer cells. Circulating levels of YKL-40 are 
      related to the degree of inflammation, tissue remodeling, fibrosis, and cancer 
      progression. METHODS AND RESULTS: We examined serum YKL-40 levels in 121 patients 
      with chronic heart failure (CHF) and 39 control subjects. The patients were 
      followed up to register cardiac events for a mean of 720 days. Serum YKL-40 
      levels were measured by sandwich enzyme-linked immunoassay. Serum YKL-40 was 
      significantly higher in New York Heart Association (NYHA) Class III/IV patients 
      than control subjects and NYHA Class I/II patients (P < .0001). Serum YKL-40 was 
      also higher in patients with cardiac events than in event-free patients (P = 
      .0023). Cutoff value of YKL-40 was determined by receiver operating 
      characteristic curve analysis. Kaplan-Meier analysis demonstrated that high level 
      of YKL-40 was associated with higher rates of cardiac events than low levels of 
      YKL-40 (P = .003). The multivariate Cox hazard analysis demonstrated that serum 
      YKL-40 level was an independent prognostic factor of cardiac events (hazard ratio 
      2.085, 95% confidence interval 1.233-3.499, P < .0048). CONCLUSIONS: Serum 
      YKL-40, a new marker of inflammation, was increased in CHF, and YKL-40 detected 
      high risk patients for adverse outcomes in CHF.
CI  - Copyright (c) 2010 Elsevier Inc. All rights reserved.
FAU - Bilim, Olga
AU  - Bilim O
AD  - First Department of Internal Medicine, Yamagata University School of Medicine, 
      Yamagata, Japan.
FAU - Takeishi, Yasuchika
AU  - Takeishi Y
FAU - Kitahara, Tatsuro
AU  - Kitahara T
FAU - Ishino, Mitsunori
AU  - Ishino M
FAU - Sasaki, Toshiki
AU  - Sasaki T
FAU - Suzuki, Satoshi
AU  - Suzuki S
FAU - Shishido, Tetsuro
AU  - Shishido T
FAU - Kubota, Isao
AU  - Kubota I
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Card Fail
JT  - Journal of cardiac failure
JID - 9442138
RN  - 0 (Adipokines)
RN  - 0 (Biomarkers)
RN  - 0 (CHI3L1 protein, human)
RN  - 0 (Chitinase-3-Like Protein 1)
RN  - 0 (Glycoproteins)
RN  - 0 (Lectins)
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
RN  - 268B43MJ25 (Uric Acid)
RN  - 9NEZ333N27 (Sodium)
RN  - AYI8EX34EU (Creatinine)
SB  - IM
MH  - Adipokines
MH  - Aged
MH  - Biomarkers/blood
MH  - Case-Control Studies
MH  - Chitinase-3-Like Protein 1
MH  - Creatinine/blood
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - Glomerular Filtration Rate
MH  - Glycoproteins/*blood
MH  - Heart Atria/pathology
MH  - Heart Failure/*blood/classification/mortality
MH  - Hospitalization
MH  - Humans
MH  - Hypertension/blood
MH  - Inflammation/blood
MH  - Lectins/*blood
MH  - Male
MH  - Natriuretic Peptide, Brain/blood
MH  - Prognosis
MH  - Proportional Hazards Models
MH  - *Severity of Illness Index
MH  - Sodium/blood
MH  - Uric Acid/blood
EDAT- 2010/11/09 06:00
MHDA- 2011/03/25 06:00
CRDT- 2010/11/09 06:00
PHST- 2010/01/18 00:00 [received]
PHST- 2010/05/03 00:00 [revised]
PHST- 2010/05/28 00:00 [accepted]
PHST- 2010/11/09 06:00 [entrez]
PHST- 2010/11/09 06:00 [pubmed]
PHST- 2011/03/25 06:00 [medline]
AID - S1071-9164(10)00253-8 [pii]
AID - 10.1016/j.cardfail.2010.05.029 [doi]
PST - ppublish
SO  - J Card Fail. 2010 Nov;16(11):873-9. doi: 10.1016/j.cardfail.2010.05.029.